C
Cezary Szczylik
Researcher at Medical University of Warsaw
Publications - 291
Citations - 30393
Cezary Szczylik is an academic researcher from Medical University of Warsaw. The author has contributed to research in topics: Renal cell carcinoma & Cancer. The author has an hindex of 49, co-authored 274 publications receiving 27380 citations. Previous affiliations of Cezary Szczylik include Military Medical Academy & Cora.
Papers
More filters
Journal ArticleDOI
Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Journal ArticleDOI
A phase III, multicenter, randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine (G) as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial.
Charles S. Fuchs,Sergio J Azevedo,Alfredo Carrato,Vincent Haddad,Lara Lipton,Jesse McGreivy,Malcolm J. Moore,Takuji Okusaka,Hanno Riess,Cezary Szczylik,Jean-Luc Van Laethem +10 more
TL;DR: Ganitumab (AMG 479) is an investigational, fully human, monoclonal antibody inhibitor of the IGF1R that has shown promise in a randomized phase II study in patients with metastatic pancreatic cancer.
Journal ArticleDOI
The role of the Fanconi anemia pathway in the pathophysiology of ovarian cancer
TL;DR: A growing number of data has shown that disruption of the FA genes may be a useful predictor of OC sensitivity to chemotherapy agents whose activity is based on DNA crosslinking mechanisms.
Proceedings ArticleDOI
Molecular characteristics of matched brain metastasis (BM) versus the primary breast cancer (PBC).
Renata Duchnowska,Jacek Jassem,Changyu Shen,Mangesh A. Thorat,Lang Li,Akira Morimiya,Q Zhao,Wojciech Biernat,T Mandat,R Staszkiewicz,W Och,W Szostak,K Gugala,Tomasz Trojanowski,Bogumiła Czartoryska-Arłukowicz,Cezary Szczylik,Harikrishna Nakshatri,P. S. Steeg,G. W. Sledge,Sunil Badve +19 more
TL;DR: Although some BM retain remarkable similarity to the PBC, majority exhibit considerable deviation in their gene expression profile, which includes greater resistance to drug therapy, increased DNA repair, a reversal back to the epithelial phenotype and decreased capacity for cell motility and invasion.
Journal ArticleDOI
Tau expression as a predictive marker in ovarian cancer patients (pts) treated with platinum/paclitaxel chemotherapy
TL;DR: In this article, the standard treatment consists of cytoreductive surgery followed by paclitaxel/platinum-based chemotherapy, which is the most lethal gynecologic cancer.